Pre-Eclampsia Clinical Trial
Official title:
Prospective Validation of Prediction Algorithms for Preeclampsia in the First-trimester of Pregnancy
This is an international multicentre prospective cohort study to validate the Bayes theorem based algorithms for the screening of pre-eclampsia (PE) in the first-trimester of pregnancy.
The investigators have previously constructed Bayes model in the first-trimester which
combines maternal characteristics and medical history (Mat-CH) together with mean arterial
pressure (MAP), uterine artery pulsatility index (PI), and serum placental growth factor
(PlGF) with a plan to assess the predictive performance.
The reference standards will be PE defined according to the International Society for the
Study of Hypertension in Pregnancy and the American College of Obstetricians and
Gynecologists. The systolic blood pressure should be >140 mm Hg and/or the diastolic blood
pressure should be >90 mmHg on at least two occasions four hours apart developing after 20
weeks' gestation in previously normotensive women and there should be proteinuria (>300 mg in
24 hours or two readings of at >2+ on dipstick analysis of midstream or catheter urine
specimens if no 24-hour collection is available). In the absence of proteinuria, new onset of
any of the following systemic findings: a) thrombocytopaenia (platelet counts <100,000 µL);
b) renal insufficiency (creatinine >1.1 mg/dL or 2-fold increase in creatinine in the absence
of underlying renal disease); c) abnormal liver function (ie, hepatic transaminase levels
twice normal); d) pulmonary oedema; or e) cerebral or visual symptoms. Preterm-PE is PE that
requires delivery before 37 weeks' gestation. If a participant fulfills the criteria for PE
by one definition and not the other she will be considered to have developed PE.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03299777 -
Correlation Between Changes in Liver Stiffness and Preeclampsia as Shown by Fibroscan
|
N/A | |
Completed |
NCT03650790 -
C1q/TNF-related Protein 9 (CTRP 9) Level in Preeclamptic Obese and Non-obese Pregnancies
|
N/A | |
Recruiting |
NCT03605511 -
TTP and aHUS in Complicated Pregnancies
|
||
Not yet recruiting |
NCT03302260 -
Identifying Methods for Postpartum Reduction of Vascular Events: Pilot Randomized Controlled Trial
|
N/A | |
Completed |
NCT02911701 -
Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features
|
Phase 4 | |
Completed |
NCT01911494 -
Community Level Interventions for Pre-eclampsia
|
N/A | |
Terminated |
NCT02025426 -
Phenylephrine Versus Ephedrine in Pre-eclampsia
|
Phase 4 | |
Completed |
NCT01352234 -
Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia
|
Phase 4 | |
Active, not recruiting |
NCT02031393 -
Establishing First Trimester Markers for the Identification of High Risk Twin
|
N/A | |
Terminated |
NCT00141310 -
Sildenafil Citrate for the Treatment of Established Pre-Eclampsia
|
Phase 2 | |
Completed |
NCT00157521 -
L-Arginine in Pre-Eclampsia
|
Phase 3 | |
Completed |
NCT04795154 -
Prenatal Yoga as Complementary Therapy of Preeclampsia
|
N/A | |
Completed |
NCT00004399 -
Randomized Study of Nimodipine Versus Magnesium Sulfate in the Prevention of Eclamptic Seizures in Patients With Severe Preeclampsia
|
N/A | |
Completed |
NCT00005207 -
Renin and Prorenin in Pregnancy
|
N/A | |
Recruiting |
NCT04551807 -
Natural Versus Programmed Frozen Embryo Transfer (NatPro)
|
Phase 3 | |
Terminated |
NCT04092829 -
Impact of Corpus Luteum Presence or Absence in the Incidence of Preeclampsia After Frozen Embryo Transfer
|
N/A | |
Recruiting |
NCT06067906 -
Weight Loss Following an Episode of Pre-eclampsia Using a Dissociated or Hypocaloric Diet in Overweight or Obese Patients
|
N/A | |
Recruiting |
NCT06317467 -
Role of Anti-C1q Autoantibodies in Pregnancy
|
||
Completed |
NCT02218931 -
ESTEEM - Effect of Simple, Targeted Diet in Pregnant Women With Metabolic Risk Factors on Pregnancy Outcomes
|
N/A | |
Active, not recruiting |
NCT04484766 -
Preeclampsia Associated Vascular Aging
|